Literature DB >> 28005687

Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents.

Linda Aurpibul1, Pagakrong Lumbiganon, Rawiwan Hansudewechakul, Suparat Kanjanavanit, Torsak Bunupuradah, Pope Kosalaraksa, Pawinee Taeprasert, Thanyawee Puthanakit.   

Abstract

We determined hepatitis B virus (HBV) suppression rates among 18 lamivudine (3TC)-experienced HBV-human immunodeficiency virus-coinfected adolescents after treatment with tenofovir disoproxil fumurate (TDF). At TDF initiation, their median age was 17.6 years, and duration of 3TC exposure was 7.3 years. Eleven patients (61%) achieved HBV DNA <60 IU/mL after 48 weeks on TDF and 3TC which was similar to adult studies, although hepatitis B surface antigen loss or hepatitis B envelope antigen seroconversion did not occur.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28005687      PMCID： PMC5348266          DOI： 10.1097/INF.0000000000001491

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  18 in total

1.  HIV and Hepatitis B coinfection among perinatally HIV-infected Thai adolescents.

Authors:  Linda Aurpibul; Pagakrong Lumbiganon; Pope Kolasaraksa; Rawiwan Hansudewechakul; Pattaratida Sa-Nguanmoo; Pawinee Taeprasert; Torsak Bunupuradah; Yong Poovorawan; Virat Sirisanthana; Thanyawee Puthanakit
Journal:  Pediatr Infect Dis J       Date:  2012-09       Impact factor: 2.129

2.  Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.

Authors:  Anders Boyd; Joël Gozlan; Sarah Maylin; Constance Delaugerre; Gilles Peytavin; Pierre-Marie Girard; Fabien Zoulim; Karine Lacombe
Journal:  Hepatology       Date:  2014-06-20       Impact factor: 17.425

3.  Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.

Authors:  Y Benhamou; M Bochet; V Thibault; V Di Martino; E Caumes; F Bricaire; P Opolon; C Katlama; T Poynard
Journal:  Hepatology       Date:  1999-11       Impact factor: 17.425

4.  Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate.

Authors:  Karine Lacombe; Joël Gozlan; Pierre-Yves Boelle; Lawrence Serfaty; Fabien Zoulim; Alain-Jacques Valleron; Pierre-Marie Girard
Journal:  AIDS       Date:  2005-06-10       Impact factor: 4.177

5.  Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol.

Authors:  Dominique Salmon-Ceron; Charlotte Lewden; Philippe Morlat; Sibylle Bévilacqua; Eric Jougla; Fabrice Bonnet; Laurence Héripret; Dominique Costagliola; Thierry May; Geneviève Chêne
Journal:  J Hepatol       Date:  2005-06       Impact factor: 25.083

6.  Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.

Authors:  Christoph Stephan; Annemarie Berger; Amina Carlebach; Thomas Lutz; Markus Bickel; Stephan Klauke; Schlomo Staszewski; Martin Stuermer
Journal:  J Antimicrob Chemother       Date:  2005-11-03       Impact factor: 5.790

Review 7.  Virology and clinical sequelae of drug-resistant HBV in HIV-HBV-coinfected patients on highly active antiretroviral therapy.

Authors:  Chloe L Thio
Journal:  Antivir Ther       Date:  2010

8.  Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.

Authors:  L Kosi; T Reiberger; B A Payer; K Grabmeier-Pfistershammer; R Strassl; A Rieger; M Peck-Radosavljevic
Journal:  J Viral Hepat       Date:  2012-03-15       Impact factor: 3.728

9.  Pediatric HIV-HBV Coinfection in Lusaka, Zambia: Prevalence and Short-Term Treatment Outcomes.

Authors:  Kathryn Peebles; Lweendo Nchimba; Roma Chilengi; Carolyn Bolton Moore; Mwangelwa Mubiana-Mbewe; Michael J Vinikoor
Journal:  J Trop Pediatr       Date:  2015-09-02       Impact factor: 1.165

10.  Hepatitis B and hepatitis C seroprevalence in children receiving antiretroviral therapy for human immunodeficiency virus-1 infection in China, 2005-2009.

Authors:  Shuntai Zhou; Yan Zhao; Yun He; Huiqin Li; Marc Bulterys; Xin Sun; Zhihui Dou; Matthew Robinson; Fujie Zhang
Journal:  J Acquir Immune Defic Syndr       Date:  2010-06       Impact factor: 3.731
View more
  1 in total

1.  Risk of Liver Fibrosis in Hepatitis B Virus and HIV Coinfected Youths Receiving Tenofovir-Containing Antiretroviral Regimen.

Authors:  Linda Aurpibul; Suparat Kanjanavanit; Apinya Leerapun; Thanyawee Puthanakit
Journal:  J Int Assoc Provid AIDS Care       Date:  2019 Jan-Dec
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.